Cumulus’ CSO appears at FT Pharma conference to discuss new dementia treatments

First published: 12th November 2021

Cumulus Neuroscience is pleased to have participated in the Financial Times Global Pharmaceutical and Biotechnology Conference. The Company’s CSO, Dr Brian Murphy, joined other dementia and digital health experts for the panel ‘Pioneering disease-modifying treatments and digital solutions for dementia’.

The panel discussed the current market for symptomatic dementia treatments, how disease-modifying treatment strategies are evolving and what level of progress we can expect in the next few years.

The speakers also considered how digital tools and technologies can support scientific advances and improve healthcare outcomes for these complex neurological conditions. Dr Murphy highlighted some of most exciting emerging approaches he has seen, drawing on his experience in AI technology. He discussed some of the barriers to progress in this area, and how Cumulus’ advanced digital biomarker platform is aiming to overcome them. The panel then considered how health systems can evolve to support these new pharmaceutical and digital interventions in the future.

Dr Murphy was joined by speakers Giovanna Lalli, Director of Scientific Affairs at UK Dementia Research Institute; Shibi Belachew, Vice President and Head of Digital Health Science at Biogen; and Christian Jung, Partner at the Dementia Discovery Fund, Cumulus' founding investor. The panel was moderated by Sarah Neville, the Financial Times’ Global Health Editor.